Research programme: asthma and inflammation therapeutics - AbbVieAlternative Names: ABT-362
Latest Information Update: 24 Jan 2013
At a glance
- Originator Abbott Laboratories
- Mechanism of Action Interleukin 13 inhibitors; Interleukin 18 inhibitors; Janus kinase 1 inhibitors; Janus kinase 3 inhibitors; Janus kinase inhibitors; Janus kinase-2 inhibitors; P38 mitogen-activated protein kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Asthma; Immunological disorders; Inflammation